Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cusatuzumab + azacitidine
- Development stage
- Phase 2
- Lead developer
- OncoVerity
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
**Cusatuzumab + azacitidine** is a combination of a monoclonal antibody and a hypomethylating agent, investigated primarily for the treatment of newly diagnosed acute myeloid leukemia (AML) in patients ineligible for intensive chemotherapy. Cusatuzumab is a high-affinity humanized IgG1 monoclonal antibody targeting CD70, a protein overexpressed on AML blasts, leading to anti-leukemic effects via enhanced antibody-dependent cellular cytotoxicity (ADCC) and inhibition of CD70/CD27 signaling. Azacitidine is a small molecule DNA hypomethylating agent that induces cell differentiation and apoptosis by incorporating into DNA and inhibiting DNA methyltransferases. The combination aims to exploit complementary pathways to improve clinical outcomes in AML. Primary clinical studies have shown that the combination is generally well tolerated and demonstrates preliminary efficacy, but further development in some settings has been discontinued due to changes in AML treatment standards.
- Other names
- cusatuzumabazacitidineVidazaJNJ-74494550JNJ74494550JNJ 74494550
02
Targets
CD70 (Cluster of Differentiation 70)DNMT (DNA methyltransferase)
Beyond the preview
Go deeper on cusatuzumab + azacitidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cusatuzumab + azacitidine.